Agilent Wins FDA Approval for PD-L1 Test to Guide Bristol Myers' Opdivo Use in GI Cancers
() -- Agilent Technologies (A) said Tuesday the US Food and Drug Administration approved its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for Bristol Myers Squibb's Opdivo and Opdivo Qvantig. This test checks patients with throat or stomach cancers for a specific protein marker, defined as a PD-L1 score of 1